39 related articles for article (PubMed ID: 8391739)
21. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus vectors as potential vaccines against herpes simplex virus.
Johnson DC
Rev Infect Dis; 1991; 13 Suppl 11():S912-6. PubMed ID: 1664127
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice.
Azuma I; Ishihara C; Iida J; Yoo YC; Yoshimatsu K; Arikawa J
Adv Exp Med Biol; 1992; 319():253-63. PubMed ID: 1329443
[TBL] [Abstract][Full Text] [Related]
25. Prospects for vaccination against herpes simplex virus.
Whitley RJ
Pediatr Ann; 1993 Dec; 22(12):726, 729-32. PubMed ID: 8139874
[No Abstract] [Full Text] [Related]
26. Herpes simplex vaccines.
Whitley RJ; Meignier B
Biotechnology; 1992; 20():223-54. PubMed ID: 1318135
[No Abstract] [Full Text] [Related]
27. Why do we lack an effective vaccine against herpes simplex virus infections?
Deshpande SP; Kumaraguru U; Rouse BT
Microbes Infect; 2000 Jul; 2(8):973-8. PubMed ID: 10962281
[TBL] [Abstract][Full Text] [Related]
28. Treatment-induced antibodies to interleukin-2.
Prümmer O
Biotherapy; 1997; 10(1):15-24. PubMed ID: 9261546
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
30. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
31. Live vaccinia virus recombinants expressing herpes simplex virus genes.
Rooney JF; Wohlenberg CR; Moss B; Notkins AL
Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
[TBL] [Abstract][Full Text] [Related]
32. From virus to vaccine: recombinant mammalian cell lines as substrates for the production of herpes simplex virus vaccines.
Lasky LA
J Med Virol; 1990 May; 31(1):59-61. PubMed ID: 2165517
[TBL] [Abstract][Full Text] [Related]
33. The mouse model and understanding immunity to herpes simplex virus.
Mester JC; Rouse BT
Rev Infect Dis; 1991; 13 Suppl 11():S935-45. PubMed ID: 1664131
[TBL] [Abstract][Full Text] [Related]
34. Recent progress in herpes simplex virus immunobiology and vaccine research.
Koelle DM; Corey L
Clin Microbiol Rev; 2003 Jan; 16(1):96-113. PubMed ID: 12525427
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
